Effect of baseline or changes in adrenergic activity on clinical outcomes in the β-Blocker Evaluation of Survival Trial

M. R. Bristow, H. Krause-Steinrauf, R. Nuzzo, Cheng Seng Liang, J. Lindenfeld, B. D. Lowes, B. Hattler, W. T. Abraham, L. Olson, S. Krueger, S. Thaneemit-Chen, J. M. Hare, H. S. Loeb, M. J. Domanski, E. J. Eichhorn, R. Zelis, P. Lavori

Research output: Contribution to journalArticlepeer-review

Abstract

Background-Adrenergic activation is thought to be an important determinant of outcome in subjects with chronic heart failure (CHF), but baseline or serial changes in adrenergic activity have not been previously investigated in a large patient sample treated with a powerful antiadrenergic agent. Methods and Results-Systemic venous norepinephrine was measured at baseline, 3 months, and 12 months in the β-Blocker Evaluation of Survival Trial (BEST), which compared placebo treatment with the β-blocker/ sympatholytic agent bucindolol. Baseline norepinephrine level was associated with a progressive increase in rates of death or death plus CHF hospitalization that was independent of treatment group. On multivariate analysis, baseline norepinephrine was also a highly significant (P

Original languageEnglish (US)
Pages (from-to)1437-1442
Number of pages6
JournalCirculation
Volume110
Issue number11
DOIs
StatePublished - Sep 14 2004

Keywords

  • Heart failure
  • Mortality
  • Nervous system, sympathetic
  • Risk factors

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Effect of baseline or changes in adrenergic activity on clinical outcomes in the β-Blocker Evaluation of Survival Trial'. Together they form a unique fingerprint.

Cite this